Фактор риска
Very high price volatility
Фактор доходности
Greatly overvalued vs peers
В портфелях гуру
Управляющий | Фонд | Доля | Изменение доли |
|---|---|---|---|
| Стив Коэн | Point72 Asset Management | 0.1% | +0.04% |
| Кен Гриффин | Citadel Advisors LLC | 0.0% | +0.00% |
О компании
HeartFlow, Inc. operates as a global medical technology firm, specializing in providing non-surgical solutions for the diagnosis and ongoing management of coronary artery disease. Its innovative HeartFlow Platform employs artificial intelligence and advanced computational fluid dynamics to generate a unique, three-dimensional digital replica of a patient's heart. This intricate model is created from a single coronary computed tomography angiography (CCTA), which is a specialized scan designed to produce highly detailed images of the heart's arterial network. The platform offers vital insights into aspects like blood flow, the extent of arterial narrowing (stenosis), and the volume and composition of any plaque present, thereby overcoming the limitations typically associated with traditional non-invasive imaging techniques. Founded in 2007, the company is headquartered in Mountain View, California.
Оценка компании
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks.
Прогноз аналитиков
The average target price of HTFL is 43.4 and suggests 7.01% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation to d